Foghorn Therapeutics Investor Presentation April 2023

Foghorn Therapeutics is a precision oncology company leveraging chromatin regulatory insights to develop first-in-class cancer therapies. The company has strategic collaborations with Lilly and Merck, with multiple clinical programs targeting genetically defined cancers and over 2.5 million potential patients in chromatin-implicated tumors.